Low-Dose Lithium May Slow Verbal Memory Decline in Seniors with Mild Cognitive Impairment

The progression of memory loss associated with early Alzheimer’s disease may be slowed by low-dose lithium, according to findings from a pilot clinical trial conducted at the University of Pittsburgh School of Medicine. The study, published today in JAMA Neurology, offers a promising, though preliminary, signal that the commonly used mood stabilizer could offer neuroprotective benefits beyond its established psychiatric applications.

A Focus on Mild Cognitive Impairment

The research centered on individuals experiencing mild cognitive impairment (MCI), often considered a transitional stage between normal age-related cognitive decline and dementia. Over a two-year period, participants with MCI received either a low dose of lithium carbonate or a placebo. Researchers observed that the group treated with lithium experienced a demonstrably slower rate of decline in verbal memory – the ability to recall words and language – a cognitive function frequently affected in the early stages of Alzheimer’s disease.

Notably, the effect was more pronounced among participants who already showed evidence of amyloid-beta plaques in their brains. These protein deposits are a hallmark of Alzheimer’s pathology. The researchers cautiously suggest that lithium may act as a “brake” on the disease’s progression, but emphasize This proves not a cure. You can identify more details about the study’s design and results on JAMA Network.

Lithium’s Emerging Role in Neuroprotection

Lithium has been used for decades to treat bipolar disorder, but the idea that it might protect against dementia isn’t new. Observational studies have suggested that older adults with bipolar disorder who accept lithium long-term often exhibit healthier brain structures. Some research indicates a correlation between lithium levels in drinking water and lower rates of dementia in certain regions. This latest pilot trial provides the first controlled clinical data to support these earlier observations.

The study included 80 participants (41 receiving lithium and 39 receiving a placebo), with an average age of around 72. Data were analyzed from August 2024 to December 2025, with a two-year follow-up period. Researchers used linear mixed-effects models to analyze the data, focusing on six pre-specified outcomes, including cognitive performance, hippocampal volume, and levels of brain-derived neurotrophic factor. While none of the outcomes reached pre-defined statistical significance, the observed trend in verbal memory decline – a 0.69 point per year difference between the lithium and placebo groups (95% CI, 0.01-1.37; P = .05) – is encouraging. Further information about the study methodology can be found on PubMed.

Safety and Tolerability: A Key Finding

A crucial aspect of this research is the demonstration that low-dose lithium was well-tolerated by the older participants. This is a significant hurdle overcome for future research, as higher doses of lithium can cause substantial side effects. The safety profile is particularly essential given the vulnerability of the population being studied.

What Does This Mean for Individuals Concerned About Cognitive Decline?

It’s important to understand that these findings are preliminary. This was a pilot study, meaning it was designed to assess feasibility and safety, not to definitively prove efficacy. The observed effect on verbal memory, while promising, requires confirmation in larger, more comprehensive Phase III clinical trials. The study does *not* suggest that individuals should self-medicate with lithium. Any use of lithium should be under the strict supervision of a qualified healthcare professional.

Mild cognitive impairment is a complex condition with many potential causes. If you are experiencing memory problems or other cognitive changes, it’s essential to consult with your doctor for a thorough evaluation. Early diagnosis and intervention are crucial for managing cognitive decline, and You’ll see many lifestyle factors – such as regular exercise, a healthy diet, and social engagement – that can support brain health.

Beyond the Study: Context and Considerations

The researchers acknowledge several limitations of the study. The single-site design and relatively small sample size limit the generalizability of the findings. The study focused specifically on verbal memory; it’s unclear whether lithium would have a similar effect on other cognitive domains. The study similarly did not investigate the optimal dose or duration of lithium treatment for MCI.

The underlying mechanisms by which lithium might exert neuroprotective effects are still being investigated. One hypothesis is that lithium modulates signaling pathways involved in neuronal survival and plasticity. Another possibility is that lithium reduces inflammation in the brain, which is increasingly recognized as a key contributor to Alzheimer’s disease. As Medical Xpress reports, lithium’s potential extends beyond mood stabilization, hinting at broader neuroprotective capabilities.

Looking Ahead: The Next Steps in Research

The positive signals from this pilot study are paving the way for a larger and longer Phase III trial. If the results are replicated in a more robust study, low-dose lithium could potentially become a relatively simple and affordable strategy for delaying cognitive decline in individuals at risk of Alzheimer’s disease. Researchers are also exploring the possibility of using biomarkers – such as amyloid-beta levels – to identify individuals who are most likely to benefit from lithium treatment. The University of Pittsburgh team is actively seeking funding to support these future research efforts.